These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36720391)

  • 1. Nitrosated Active Pharmaceutical Ingredients - Lessons Learned?
    Holzgrabe U
    J Pharm Sci; 2023 May; 112(5):1210-1215. PubMed ID: 36720391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Nitrite Excipient Database: A Useful Tool to Support N-Nitrosamine Risk Assessments for Drug Products.
    Boetzel R; Schlingemann J; Hickert S; Korn C; Kocks G; Luck B; Blom G; Harrison M; François M; Allain L; Wu Y; Bousraf Y
    J Pharm Sci; 2023 Jun; 112(6):1615-1624. PubMed ID: 35500671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals.
    Schlingemann J; Burns MJ; Ponting DJ; Martins Avila C; Romero NE; Jaywant MA; Smith GF; Ashworth IW; Simon S; Saal C; Wilk A
    J Pharm Sci; 2023 May; 112(5):1287-1304. PubMed ID: 36402198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitroso Impurities in Drug Products: An Overview of Risk Assessment, Regulatory Milieu, and Control Strategy.
    Charoo NA; Dharani S; Khan MA; Rahman Z
    AAPS PharmSciTech; 2023 Feb; 24(2):60. PubMed ID: 36759424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitrosamine Impurities in Pharmaceuticals: An Empirical Review of their Detection, Mechanisms, and Regulatory Approaches.
    Bhirud D; Agrawal G; Shah H; Patel A; Palkar MB; Bhattacharya S; Prajapati BG
    Curr Top Med Chem; 2024; 24(6):503-522. PubMed ID: 38321910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive review of sources of nitrosamine contamination of pharmaceutical substances and products.
    Akkaraju H; Tatia R; Mane SS; Khade AB; Dengale SJ
    Regul Toxicol Pharmacol; 2023 Mar; 139():105355. PubMed ID: 36792049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-Nitrosamine Formation in Pharmaceutical Solid Drug Products: Experimental Observations.
    Moser J; Ashworth IW; Harris L; Hillier MC; Nanda KK; Scrivens G
    J Pharm Sci; 2023 May; 112(5):1255-1267. PubMed ID: 36736774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analytical Methodologies to Detect N-Nitrosamine Impurities in Active Pharmaceutical Ingredients, Drug Products and Other Matrices.
    Manchuri KM; Shaik MA; Gopireddy VSR; Naziya Sultana ; Gogineni S
    Chem Res Toxicol; 2024 Sep; 37(9):1456-1483. PubMed ID: 39158368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bumetanide as a Model NDSRI Substrate: N-nitrosobumetanide Impurity Formation and its Inhibition in Bumetanide Tablets.
    Shakleya D; Asmelash B; Alayoubi A; Abrigo N; Mohammad A; Wang J; Zhang J; Yang J; Marzan TA; Li D; Shaklah M; Alsharif FM; Desai S; Faustino PJ; Ashraf M; O'Connor T; Vera M; Raw A; Sayeed VA; Keire D
    J Pharm Sci; 2023 Dec; 112(12):3075-3087. PubMed ID: 37364772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified NAP test: A simple and Responsive Nitrosating Methodology for Risk Evaluation of NDSRIs.
    Sharma N; Patel R; Bothara T; Jain S; Shah RP
    J Pharm Sci; 2023 May; 112(5):1333-1340. PubMed ID: 36871894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of N-Nitrosamine Formation in Drug Products: A Model Study.
    Nanda KK; Tignor S; Clancy J; Marota MJ; Allain LR; D'Addio SM
    J Pharm Sci; 2021 Dec; 110(12):3773-3775. PubMed ID: 34400183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling the Impact of Excipients Selection on Nitrosamine Formation towards Risk Mitigation.
    Berardi A; Jaspers M; Dickhoff BHJ
    Pharmaceutics; 2023 Jul; 15(8):. PubMed ID: 37631229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a Novel LC-MS/MS Based Analytical Method for the Risk Assessment of Nitrosamines in Pharmaceutical Products and Packaging Materials.
    Kartop RA; Güleli M; Faruzlu FA; Çalışkan C
    J Pharm Sci; 2024 Jun; 113(6):1597-1606. PubMed ID: 38253223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical and Science-Based Strategy for Establishing Acceptable Intakes for Drug Product
    Dobo KL; Kenyon MO; Dirat O; Engel M; Fleetwood A; Martin M; Mattano S; Musso A; McWilliams JC; Papanikolaou A; Parris P; Whritenour J; Yu S; Kalgutkar AS
    Chem Res Toxicol; 2022 Mar; 35(3):475-489. PubMed ID: 35212515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA).
    Kruhlak NL; Schmidt M; Froetschl R; Graber S; Haas B; Horne I; Horne S; King ST; Koval IA; Kumaran G; Langenkamp A; McGovern TJ; Peryea T; Sanh A; Siqueira Ferreira A; van Aerts L; Vespa A; Whomsley R
    Regul Toxicol Pharmacol; 2024 Jun; 150():105640. PubMed ID: 38754805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of nitrosamine contaminants in drug samples: Has the crisis been overcome?
    Schmidtsdorff S; Neumann J; Schmidt AH; Parr MK
    Arch Pharm (Weinheim); 2023 Feb; 356(2):e2200484. PubMed ID: 36461687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of acceptable daily intake values based on modeling and in vivo mutagenicity of NDSRIs of fluoxetine, duloxetine and atomoxetine.
    Jolly RA; Cornwell PD; Noteboom J; Sayyed FB; Thapa B; Buckley LA
    Regul Toxicol Pharmacol; 2024 Sep; 152():105672. PubMed ID: 38968965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Elemental Impurities Excipient Database: A Viable Tool for ICH Q3D Drug Product Risk Assessment.
    Boetzel R; Ceszlak A; Day C; Drumm P; Gil Bejar J; Glennon J; Harris L; Heghes CI; Horga R; Jacobs PL; Keurentjes WJTM; King F; Lee CW; Lewen N; Marchant CA; Maris FA; Nye W; Powell S; Rockstroh H; Rutter L; Schweitzer M; Shannon E; Smallshaw L; Teasdale A; Thompson S; Wilkinson D
    J Pharm Sci; 2018 Sep; 107(9):2335-2340. PubMed ID: 29679706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals.
    Wichitnithad W; Nantaphol S; Noppakhunsomboon K; Rojsitthisak P
    Saudi Pharm J; 2023 Feb; 31(2):295-311. PubMed ID: 36942272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-nitrosamine Mitigation with Nitrite Scavengers in Oral Pharmaceutical Drug Products.
    Bayne AV; Misic Z; Stemmler RT; Wittner M; Frerichs M; Bird JK; Besheer A
    J Pharm Sci; 2023 Jul; 112(7):1794-1800. PubMed ID: 37023856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.